17 results about "Immunologic Procedures" patented technology

The invention discloses a quadruple mRNA vaccine for preventing feline infectious diseases and application thereof, the quadruple mRNA vaccine can simultaneously prevent feline rabies, feline calicivirus disease, feline panleucopenia and feline rhinotracheitis through one-time immunization, and experiments show that the vaccine is relatively safe and strong in efficacy, the injection cost is reduced, and the vaccine is suitable for clinical application. The immune procedure is optimized, and the method has great significance in preventing cat infectious diseases.

The invention discloses a breeding informatization management system based on intelligent agriculture big data, and relates to the technical field of big data management, and the system comprises a breeding file establishment module which is used for taking the specific immune response intensity and stability of a target pathogen as core breeding indexes, screening excellent parents to construct a basic breeding group, and establishing a breeding file; establishing a breeding file containing pedigree, genotype and immune related molecular markers; the immune archive binding module is used for creating a structured immune archive for the individual based on the archive and binding a unique identifier; the immune program formulating module is used for formulating differentiated immune programs according to genetic background layering; the immune program optimization module is used for scanning an identifier at an immune spot to automatically match an optimization scheme; and the multi-index combined seed selection module is used for quantifying the post-immune titer index into a new breeding character and feeding the new breeding character back to the breeding system, so that closed-loop optimization is realized. According to the method, the breeding efficiency, the immune precision and the group disease resistance can be remarkably improved.

Provided are a Trichinella spiralis vaccine kit based on a prime-boost sequential immunization program and use thereof, improving the protective effect against trichinosis. The kit is divided into two parts; the first part is a Trichinella spiralis recombinant protein vaccine having an amino acid sequence set forth in SEQ ID NO. 1 or SEQ ID NO. 2, and the second part is a recombinant adenovirus expressing an amino acid sequence set forth in SEQ ID NO. 1. The prime-boost immunization strategy not only effectively avoids the deficiency associated with a single-type Trichinella spiralis vaccine, but also significantly improves the efficacy and durability of the immune response.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

The invention discloses a porcine pseudorabies GE purification scheme, and the purification method comprises the following steps: S1, pig farm environment background evaluation and odor purification device installation; s2, evaluating the health status of the swinery and optimizing an immune program; s3, epidemic disease purification and odor cooperative control; s4, environment-epidemic disease linkage monitoring and early warning are carried out; and S5, maintaining the purification effect. The environment stress is reduced through the odor purification device, the immunity of pigs is enhanced, and the propagation opportunity of PRV is reduced; biodegradation and photocatalysis technologies are combined, so that a remarkable inactivation effect on PRV aerosol is achieved; establishing a first machine learning-based environment parameter and PRV propagation risk prediction model to realize early warning; the use amount of disinfectants is reduced by 40%, the use amount of antibiotics is reduced, and green breeding is achieved; the PRV purification period can be shortened, the maintenance cost is reduced, and meanwhile, the working environment of a pig farm is remarkably improved.

Provided are a rabies virus G protein mutant, a preparation method and application thereof, and relate to the technical field of biological medicine. The rabies virus G protein mutant is obtained by point mutation on the extracellular domain of the G protein. The mutant realizes soluble expression of the extracellular domain of the G protein, and can induce production of high-titer neutralizing antibodies. Compared with commercial human rabies vaccine and canine rabies vaccine, the mutant has more excellent cellular immune and antibody immune responses, and is expected to reduce the number of inoculations, shorten the immunization program and reduce the immunization dose.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The present invention relates to the field of biomedicine, and more particularly to rabies virus G protein mutants, preparation methods, and applications thereof. The rabies virus G protein mutants of the present invention are obtained by point mutation of the G protein's extracellular domain. These mutants achieve soluble expression of the G protein's extracellular domain and can induce the production of high-titer neutralizing antibodies. Compared to commercial human and canine rabies vaccines, these mutants exhibit superior cellular and antibody immune responses, potentially reducing the number of vaccinations, shortening the immunization schedule, and reducing the immunization dose.

The invention relates to the technical field of vaccine preparation, in particular to a bivalent subunit vaccine based on rabbit hemorrhagic disease virus type 2 VLPs and pasteurella multocida OMV as well as a preparation method and application of the bivalent subunit vaccine based on the rabbit hemorrhagic disease virus type 2 VLPs and the pasteurella multocida OMV. The vaccine is obtained by combining type 2 rabbit hemorrhagic disease virus VLPs and pasteurella multocida OMV; the mass ratio of the type 2 rabbit hemorrhagic disease virus VLPs to the pasteurella multocida OMV is 1: 1 or 1: 2. The invention aims to construct a novel bivalent vaccine capable of preventing RHDV2 and Pm infection at the same time. Establishing a preparation process of VLPs of RHDV2 and OMV of Pm, and efficiently combining the VLPs and the OMV to form a bivalent subunit vaccine; the optimal immune dose and the scientific immune procedure are defined by performing immune test and challenge protection effect evaluation on the domestic rabbits. The research aims at providing a scientific basis for developing the RHDV2 and rabbit Pm bigeminy subunit vaccine, has industrial development potential and has important significance on high-quality development of the special rabbit industry.

The invention belongs to the field of immunology, and particularly relates to a method for constructing an animal model and application thereof. The method comprises the following steps: firstly, providing a method for constructing a mouse model, namely constructing four transgenic mice by using artificial chromosomes, two different DNA recombinase and three different reporter genes, and mating to obtain the transgenic mice carrying the three different reporter genes at the same time, the mouse can be used for tracking Th1 cell differentiation and central memory T cell development in an animal body. The invention also provides a method for evaluating the immune efficacy of the vaccine, which comprises the following steps: immunizing a mouse according to an immune procedure and a dose capable of causing immune response, extracting lymphocytes of the mouse, performing flow cytometry staining, and observing a result. Through a constructed mouse model, it is found that differentiated Th1 type effector cells capable of stably expressing T-bet can be developed into CCR7 + CD4 + TCM cells, and analysis of functions and development differentiation of the cells can provide a new thought for development of cellular immune vaccines with higher effector functions and long protection periods.

The invention provides an immune injection method of a rabies vaccine for Mongolia cattle, which adopts a dog rabies inactivated vaccine to immunize the Mongolia cattle, and comprises the following steps: injecting 2ml of rabies inactivated vaccine for each Mongolia cattle, and injecting for the second time after 17-21 days. Test results show that the Mongolia cattle can generate protective antibodies 17 days after first injection, the antibody titer mean value reaches a peak value 115 days after second injection, and the immune protection period can last for at least 12 months. The invention also provides an alternative scheme of one-time 5ml injection, and also has a good immune effect. The method can effectively prevent rabies of Mongolian cattle, is suitable for a desert steppe grazing environment, and has popularization and application values.

The application provides a kind of preventive inoculation information quick entry and check device, relating to medical information technology field, including information collection registration module, database storage module, central check processing module, interactive alarm module and inoculation execution confirmation module;The application obtains the identity of the recipient and vaccine information through multi-modal mode, and encapsulates into standardized data packet, avoids the problem of low efficiency of manual entry, then the central check processing module carries out real-time, multi-dimensional logical reasoning calculation based on dynamic rules, and the back-end operation and management indexes such as cold chain quality and inventory status are preposed as real-time check dimensions as important as medical contraindications and immunization programs, so that the use of invalid vaccine, inventory shortage misregistration and other difficult to prevent risks are actively intercepted before inoculation occurs, and further, the man-machine collaborative decision mechanism of alarm state is introduced, which ensures that the safety bottom line is not broken, and gives the final decision-making right to medical staff in complex situation.

The invention relates to the technical field of biological medicines, in particular to a rabies virus G protein mutant as well as a preparation method and application thereof. The rabies virus G protein mutant is obtained by carrying out point mutation on an extracellular domain of G protein, the mutant realizes soluble expression of the extracellular domain of the G protein, can induce generation of a high-titer neutralizing antibody, and has more excellent cellular immunity and antibody immune response compared with commercial human rabies vaccines and canine rabies vaccines; the inoculation frequency is expected to be reduced, the immune procedure is shortened, and the immune dosage is reduced.

The application belongs to the technical field of genetic engineering, and provides an oahs gene deletion strain and application thereof in prevention of Streptococcus suis type 2 infection.The oahs gene deletion strain, namely SC19-ΔOAHS, has very low virulence and is basically non-toxic.The mutant strain has basically no infection damage to mice when the mice are immunized with a large dose of live bacteria, and the antibody titer in the mice is obviously increased with the aid of an adjuvant, so that the immunoprotection can be successfully established.The immunoprotection established after a normal immunization procedure can help the mice effectively resist the infection of Streptococcus suis type 2, reduce the mortality and bacterial colonization in the body.The preparation method of SC19-ΔOAHS is simple, and the strain can be prepared in a short period of time, is simple to culture, and does not need other complex treatment as a vaccine, and can be used after washing and mixing with an adjuvant.SC19-ΔOAHS has the potential to be used as a live bacteria vaccine against Streptococcus suis infection in pigs.

The invention provides a recombinant antigen protein for detecting porcine circovirus type 3 as well as a preparation method and application of the recombinant antigen protein. The recombinant antigen protein has an amino acid sequence as shown in SEQ ID NO.2; or the protein is derived protein which is obtained by replacing, increasing or truncating an amino acid sequence shown as SEQ ID NO.2 and has the capability of combining with a porcine circovirus type 3 antibody. The ELISA detection kit containing the recombinant antigen protein is simple and convenient to operate, good in specificity and high in sensitivity, can be popularized on a large scale and is used for detecting the recombinant antigen protein of PCV3 and a detection product with the antigen protein, such as an antibody detection kit and the like, so that real-time monitoring on the immune level of herd pigs PCV3 is realized; and a scientific and flexible pig herd epidemic disease immune program is established.

The invention relates to the technical field of livestock and poultry viral epidemic disease immunoprophylaxis, and particularly discloses a method for preventing poultry viral arthritis. Comprising a mixed strain of avian reoviruses S1133 strain and 1733 strain, a natural immunopotentiator containing astragalus polysaccharide, beta-glucan and eucommia polysaccharide, and a nano adjuvant system consisting of hydroxyapatite nanoparticles and vitamin E, the preparation method comprises the following steps: firstly, inactivating the double strains to prepare a vaccine basic solution, then adding the natural immunopotentiator for synergistic treatment, and finally mixing with the nano adjuvant through a specific ultrasonic process to prepare the final vaccine. According to the application, the mucosal immunity is effectively stimulated while systematic immunity is established through a staged immune procedure of combining primary subcutaneous inoculation and secondary drinking immunization; the complete technical scheme is formed through cooperation of multiple strains and the synergistic interaction effect of the nano adjuvant in combination with environmental control and nutrition intervention measures, and the vaccine has the advantages of being comprehensive in immune protection and wide in applicability.

The invention discloses a preparation method of a biological agent for enhancing immune response of an infant hepatitis B vaccine generated by an HBsAg positive mother based on a dendritic cell exosome. The preparation method comprises the following steps: obtaining the dendritic cell exosome; preparing a Dex + HepB biological preparation; establishing an HBV intrauterine exposure animal model; and the Dex + HepB biological agent is used for intervening in HBV intrauterine exposed animals. In application verification, an HBV intrauterine exposure mouse model is constructed to simulate the immune state of an infant born by an HBsAg positive mother. And then, according to an immune procedure of 0-2-4 weeks, injecting the prepared Dex + HepB biological agent into the body of a model mouse. Experimental results show that the preparation can effectively improve the proportion of CD4T cells in the spleen of a mouse, improve the expression level of Th2 type cytokines and remarkably enhance the generation of anti-HBs, so that the immune response of the mouse to hepatitis B vaccines is comprehensively improved.